Eiger Bio Pharmaceuticals To Focus On Metabolic Diseases With Avexitide; David Apelian Takes Helm As CEO

Jun 29, 2023•about 2 years ago

Position

Chief Executive Officer

Company

Eiger BioPharmaceuticals

David Apelian

Palo Alto

Description

Eiger BioPharmaceuticals, Inc. , a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization review, the Company will focus its development efforts on advancing avexitide in hyperinsulinemic hypoglycemia indications. The Company will continue to commercialize Zokinvy® for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies

Company Information

Company

Eiger BioPharmaceuticals

Location

Palo Alto, California, United States

About

Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for are diseases. Eiger's lead product candidate, avexitide, is a well characterized, first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Avexitide is the only drug in development for PBH with Breakthrough Therapy designation from the FDA. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Related People

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months